Advertisement
Advertisement
U.S. markets open in 3 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

TXMD Jan 2023 2.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 03:45PM EDT. Market open.
Advertisement
Full screen
Previous Close0.0500
Open0.0500
Bid0.0000
Ask0.1000
Strike2.50
Expire Date2023-01-20
Day's Range0.0500 - 0.0500
Contract RangeN/A
Volume40
Open Interest688
  • Business Wire

    TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

    BOCA RATON, Fla., August 08, 2022--TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets.

  • American City Business Journals

    Pharma firm receives $15M investment after canceled merger

    TherapeuticsMD secured a $15 million equity investment from New York advisory Rubric Capital Management weeks after its deal to be acquired by an affiliate of private equity firm EW Healthcare Partners fell through. The Boca Raton-based women's health care company will use the private investment to fulfill its near-term working capital requirements, according to a news release. “With our investment, TherapeuticsMD will have the time and resources to thoroughly evaluate its strategic options with the objective of securing the best outcome for all shareholders," said David Rosen, managing partner of Rubric Capital.

  • Business Wire

    TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

    BOCA RATON, Fla., August 01, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women’s healthcare company, announced today that it has received a $15 million private investment in the Company’s common stock and a new series of preferred stock ("PIPE") from Rubric Capital Management LP ("Rubric"). TherapeuticsMD expects to use the proceeds from the transaction to fulfill its near-term operating capital requirements.

Advertisement
Advertisement